World's first device-based treatment for small abdominal aortic aneurysms based...
World's first device-based treatment for small abdominal aortic aneurysms based on revolutionary new treatment paradigm
The Angiolutions device is a first-of-its-kind device stopping the life-threatening progression of small abdominal aortic aneurysm (AAA) – a pathological dilation of the aorta.
Angiolutions’ award-winning & patent-protected soluti...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
aortoseal
A minimally invasive and durable endograft fastening solutio...
6M€
Cerrado
RT3S
Real Time Simulation for Safer vascular Stenting
5M€
Cerrado
TIN2013-47913-C3-1-R
MODELOS DEFORMABLES PARA EL TRATAMIENTO ENDOVASCULAR Y SEGUI...
116K€
Cerrado
TIN2013-47913-C3-2-R
MODELOS DEFORMABLES PARA EL TRATAMIENTO ENDOVASCULAR Y SEGUI...
80K€
Cerrado
Filterlex
Filterlex is a unique full body embolic protection device...
71K€
Cerrado
SpiraStent
DEVELOPMENT OF A SPIRAL LAMINAR FLOW INDUCING ENDOVASCULAR S...
71K€
Cerrado
Duración del proyecto: 26 meses
Fecha Inicio: 2023-10-24
Fecha Fin: 2025-12-31
Líder del proyecto
ANGIOLUTIONS GMBH
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The Angiolutions device is a first-of-its-kind device stopping the life-threatening progression of small abdominal aortic aneurysm (AAA) – a pathological dilation of the aorta.
Angiolutions’ award-winning & patent-protected solution leverages a fundamentally new understanding of AAA growth discovered by the founders at Stanford University. They showed that stiffness gradients between the compliant (healthy) aorta and the adjacent stiff (diseased) aneurysm serve as a motor for AAA growth.
Based on this principle & together with key physicians, we developed a minimally-invasive, non-active aortic implant (class III). The nitinol-based device is positioned adjacent to the aneurysm sack via simple, catheter-based implantation. It is specifically designed to focally increase aortic stiffness in the compliant AAA neck region, thereby reducing stiffness gradients towards the stiff AAA sack that drive aneurysm growth.Hereby, we achieve a fast, low-risk, size-stabilizing treatment of small AAA.